AAP issues recommendations for pediatric RSV vaccination in 2026-2027 season
· Medical Xpressby Elana Gotkine
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
reputable news agency
proofread
The GIST Add as preferred source
New guidelines expand the categories of high-risk children eligible for respiratory syncytial virus (RSV) vaccination and address COVID-19 vaccines for children in two policy statements and accompanying technical reports from the American Academy of Pediatrics (AAP), published online Sept. 2 in Pediatrics.
The AAP Committee on Infectious Diseases updated recommendations for using RSV vaccination to prevent lower respiratory tract infection in infants and children. The AAP recommends RSV immunization for all infants younger than 8 months born during or entering their first RSV season unless there is documented protection from prenatal vaccination.
In addition, RSV vaccination is recommended for children ages 8 through 19 months at high risk for severe RSV disease who are entering their second RSV season. These high-risk children include those born preterm, regardless of the need for medication or other support; children with hemodynamically significant congenital heart disease; children with anatomic pulmonary abnormalities or neuromuscular disorders; and children with Down syndrome or other chromosomal differences.
The AAP recommends the 2026–2027 COVID-19 vaccine for all infants and children ages 6 through 23 months who do not have contraindications. In addition, a single dose of age-appropriate 2026–2027 COVID-19 vaccine is recommended for all children ages 2 through 18 who have an increased risk for severe COVID-19, irrespective of prior COVID-19 vaccination status.
"The evidence is clear: these products work very well to prevent RSV and keep infants out of the hospital," Sean T. O'Leary, M.D., M.P.H., chair of the RSV immunization subgroup of the AAP Committee on Infectious Diseases, said in a statement. "We're already seeing real-world impact."
Publication details
Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report, Pediatrics (2026). DOI: 10.1542/peds.2026-079049
Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Policy Statement, Pediatrics (2026). DOI: 10.1542/peds.2026-079045
Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Technical Report, Pediatrics (2026). DOI: 10.1542/peds.2026-079046
Journal information: Pediatrics
Key medical concepts
Clinical categories
PediatricsInfectious diseasesCommon illnesses & PreventionChildren's health Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Copyright © 2026 HealthDay. All rights reserved.
Citation: AAP issues recommendations for pediatric RSV vaccination in 2026-2027 season (2026, September 10) retrieved 10 September 2026 from https://medicalxpress.com/news/2026-09-aap-issues-pediatric-rsv-vaccination.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.